Combination of progesterone receptor antagonist with nonsteroidal atiestrogenos for use in Diseases mediated by BRCA (tumor suppressor genes)

摘要

Combination of progesterone receptor antagonist 11beta - (4-acetylphenyl) - 17alfa 17beta hydroxy - (1,1,2,2,2 - pentafluoroetil) - estra - 4.9 - dien - 3-one, or a derivative or an Analogue of this acceptable for pharmaceutical use, with at least unantiestrogeno non steroidalAnd the use of this Combination for prophylaxis and Treatment of diseases mediated by BRCA1 or BRCA2 tumor suppressor genes 1 and 2).Nonsteroidal Antiestrogens which can be combined with the antagonistadel 11beta - progesterone receptor (4-acetylphenyl) - 17alfa 17beta hydroxy - (1,1,2,2,2 - pentafluoroetil) - estra - 4.9 - dien - 3-one are, for example, Raloxifene, tamoxifen, toremifene, droloxifene, lasofoxifene, arzoxifene, gw5638, Em - 800, ybasedoxifeno idoxifene.Claim 1: a Pharmaceutical Combination according to claim 1, wherein the combination comprises the progesterone receptor antagonist 11beta - (4 - acetyl phenyl) - 17alfa 17beta hydroxy - (1,1,2,2,2 - pentafluoroetil) - estra - 4.9 - dien - 3-one, an anti estrogen is not Teroidal and an agent with pharmacological activity.Claim 7: a Pharmaceutical Combination according to claim 8, wherein the conactividad pharmacological Agent is a cytotoxic Agent.